Am J Transplant, Volume 18, Suppl 3 Archives - Page 127 of 211 - ATC Abstracts

2018 American Transplant Congress
Impact of Immunogenicity on Kidney Allograft Survival in Patients Treated with Induction Therapy
D. Bekbolsynov, B. Mierzejewska, M. Rees, J. Ortiz, O. Ekwenna, S. Stepkowski.
University of Toledo, Toledo.
Background. The induction therapy is currently used in the majority of kidney transplant recipients, regardless of their level of donor/recipient compatibility. We examined whether lower…
2018 American Transplant Congress
Alemtuzumab Induction is Effective and Safe in Elderly Kidney Transplant Recipients
A. Toledo, K. Szempruch, P. Serrano, K. Andreoni, T. Kozlowski.
University of North Carolina, Chapel Hill.
Purpose of this study is to determine safety of Alemtuzumab (Ab) in elderly kidney recipients.MethodsThis is a retrospective single center cohort analysis concerning kidney transplant…
2018 American Transplant Congress
Development of a Screening Tool to Predict Chronic Kidney Disease Risk in Post-Nephrectomy Living Kidney Donors
J. Na,¹ J. Park,¹ M-.G. Yoon,¹ H. Lee,² Y. Yoon,³ K. Huh,⁴ M. Kim,⁴ S. Kim,⁴ Y. Kim,⁴ W. Han.¹
¹Department of Urology, Yonsei University College of Medicine, Urological Science Institute, Seoul, Korea; ²Department of Urology, National Health Insurance Service Ilsan Hospital, Goyang-si, Korea; ³Department of Urology, Hanyang University Medical Center, Seoul, Korea; ⁴Department of Surgery-Transplantation, Yonsei University College of Medicine, Seoul, Korea.
Purpose: We aimed to develop a prediction models of chronic kidney disease (CKD) for the 1-year period after donor nephrectomy in living donors.Materials and Methods:…
2018 American Transplant Congress
Non-Medical Factors Predict Receipt and Type of Kidney Transplant
H. Wesselman,¹ X. Li,¹ J. Chang,¹ K. Kendall,¹ J. Pleis,¹ E. Croswell,¹ M. Dew,¹ R. Shapiro,² L. Myaskovsky.³
¹University of Pittsburgh, Pittsburgh, PA; ²Recanati/Miller Transplantation Institute, New York, NY; ³University of New Mexico, Albuquerque, NM.
African Americans have a higher incidence of end-stage kidney disease but lower rates of both deceased and living donor kidney transplant (DDKT and LDKT) compared…
2018 American Transplant Congress
The Incidence and Risk Factors for Non – Adherence to Medical Treatment among Patients after Kidney Transplantation
T. Mashraki,^1,2,3 B. Rozen-Zvi,^1,4 E. Mor,^2,4 A. Yussim,^1,2 C. Avry,^1,4 R. Rahamimov.^1,2,3
¹Nephrology and Hypertension, Rabin Medical Center, Petach Tikva, Israel; ²Transplantation, Rabin Medical Center, Petach Tikva, Israel; ³Faculty of Health Science, Ariel University Center of Samaria, Ariel, Israel; ⁴Sackler Faculty of Medicine, Tel- Aviv University, Tel- Aviv, Israel.
Background: Nonadherence to medical treatment is an important risk factor for acute rejection and graft loss. In this study we sought to determine the prevalence…
2018 American Transplant Congress
The Impact of the Influenza Vaccine on Pediatric Kidney Transplant Outcomes
M. Camerino,¹ S. Jackson,² S. Chinnakotla,³ P. Verghese.¹
¹Department of Pediatrics, University of Minnesota, Minneapolis, MN; ²Fairview Health Services, Minneapolis, MN; ³Department of Surgery, University of Minnesota, Minneapolis, MN.
The influenza vaccine has been associated with de novo DSA and rejection in adult kidney recipients. This risk has not been adequately assessed in pediatric…
2018 American Transplant Congress
Impact of Once-Daily Tacrolimus on Adherence in Stable Adolescent and Young Adult Renal Transplant Recipients
M. Moss,¹ J. Goebel,² M. Bock.²
¹Pharmacy, Children's Hospital Colorado, Aurora, CO; ²Pediatric Nephrology, Children's Hospital Colorado, Aurora, CO.
Medication non-adherence is a risk factor for graft dysfunction and loss among renal transplant recipients (RTRs), especially adolescents and young adults (AYA). Number of medication…
2018 American Transplant Congress
A Review of Pediatric Drug Development Programs and FDA Labeling for Immunosuppressive Drugs in Organ Transplant Patients
G. Burckart,¹ M. Cavaillé-Coll,² A. Duong,³ L. Hothem,⁴ R. Albrecht.²
¹Office of Clinical Pharmacology, Office of Translational Science, CDER, US Food and Drug Administration, Silver Spring, MD; ²Division of Transplant and Opthalmology Products, Office of New Drugs, CDER, US Food and Drug Administration, Silver Spring, MD; ³Tauro University, New York, NY; ⁴University of North Carolina, Chapel Hill, NC.
The development of drugs for organ transplantation spanned the time before and after pediatric regulatory requirements under the Best Pharmaceuticals for Children Act (BPCA) and…
2018 American Transplant Congress
Validating MORAL in Living Donor Liver Transplantation for Hepatocellular Carcinoma
A. Bhatti, A. Qureshi, N. Khan, M. Butt, A. Waheed, A. Rana, F. Dar.
Hepatobiliary Surgery and Liver Transplantation, Hepatology, Radiology, Shifa International Hospital, Islamabad, Pakistan.
The “Model of Recurrence after Liver Transplant” (MORAL) study has identified certain pre and post operative variables that have significant impact on recurrence free survival…
2018 American Transplant Congress
A Long-Term Experience with Expansion of Milan Criteria for Liver Transplant Recipients
S. Commander,¹ B. Shaw,¹ L. Washburn,² D. Yoeli,² A. Rana,² J. Goss.²
¹Duke University, Durham, NC; ²Baylor College of Medicine, Houston, TX.
Background: The Milan Criteria (MC) have historically determined eligibility for transplantation for hepatocellular carcinoma (HCC). The United Network for Organ Sharing (UNOS) Region 4 expanded…